AstraZeneca sells £2.7bn block to fund cancer drug deal

Pharmaceutical giant AstraZeneca has entered into a collaboration agreement with Japanese pharmaceutical company Daiichi Sankyo to develop a new antibody-drug conjugate which it is hoped will revolutionise cancer treatment. The deal is being funded through an equity capital raise.